130 related articles for article (PubMed ID: 35461059)
1. Negative interpretation of ambiguous bodily information by patients with relapsing-remitting multiple sclerosis.
Hosseinchi P; Ghalibaf E; Dehghani A; Khatibi A
Mult Scler Relat Disord; 2022 Jun; 62():103808. PubMed ID: 35461059
[TBL] [Abstract][Full Text] [Related]
2. Health anxiety and the negative interpretation of children's bodily symptoms in mothers of cancer patients.
Hosseinchi P; Ghalibaf E; Kamyab G; Eghbali A; Khatibi A
J Cancer Surviv; 2024 Feb; 18(1):157-164. PubMed ID: 37470950
[TBL] [Abstract][Full Text] [Related]
3. The impact of health anxiety in patients with relapsing remitting multiple sclerosis: Misperception, misattribution and quality of life.
Hayter AL; Salkovskis PM; Silber E; Morris RG
Br J Clin Psychol; 2016 Nov; 55(4):371-386. PubMed ID: 26806805
[TBL] [Abstract][Full Text] [Related]
4. Fear of relapse in patients suffering from RRMS influence their quality of life.
Khatibi A; Weiland TJ; Dehghani M
Mult Scler Relat Disord; 2021 Sep; 54():103137. PubMed ID: 34252838
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
7. Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting multiple sclerosis.
Broche-Pérez Y; Jiménez-Morales RM; Monasterio-Ramos LO; Vázquez-Gómez LA; Fernández-Fleites Z
Neurologia (Engl Ed); 2022 Jul; ():. PubMed ID: 35907628
[TBL] [Abstract][Full Text] [Related]
8. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
Siddiqui MK; Singh B; Attri S; Veraart C; Harty G; Wong SL
Curr Med Res Opin; 2020 May; 36(5):809-826. PubMed ID: 32129684
[No Abstract] [Full Text] [Related]
9. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
10. Plasma thiol/disulphide homeostasis changes in patients with relapsing-remitting multiple sclerosis.
Ozben S; Kucuksayan E; Koseoglu M; Erel O; Neselioglu S; Ozben T
Int J Clin Pract; 2021 Jul; 75(7):e14241. PubMed ID: 33891773
[TBL] [Abstract][Full Text] [Related]
11. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes.
Diržiuvienė B; Mickevičienė D
Mult Scler Relat Disord; 2022 Mar; 59():103558. PubMed ID: 35123292
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients.
Khatibi A; Moradi N; Rahbari N; Salehi T; Dehghani M
Front Psychiatry; 2020; 11():226. PubMed ID: 32265764
[TBL] [Abstract][Full Text] [Related]
13. Abnormalcortical thickness in relapsing-remitting multiple sclerosis, correlations with cognition impairment, and effect of modified Bushenyisui decoction on cognitive function of multiple sclerosis.
Zhao X; Yang T; Cheng F; Yang S; Zhu W; Li S; Fan Y
J Tradit Chin Med; 2021 Apr; 41(2):316-325. PubMed ID: 33825413
[TBL] [Abstract][Full Text] [Related]
14. Is there a relationship between anxiety and depression with respiratory functions in patients with relapsing-remitting multiple sclerosis?
Eren F; Demir A; Ozkan B
Mult Scler Relat Disord; 2021 Jul; 52():103023. PubMed ID: 34049218
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
[TBL] [Abstract][Full Text] [Related]
16. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
[TBL] [Abstract][Full Text] [Related]
17. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later.
Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Duyverman L; van der Zande A; Valkenburg-Vissers J; van Droffelaar M; Lemmens W; Donders R; Visser LH
BMC Res Notes; 2016 Jul; 9():375. PubMed ID: 27473375
[TBL] [Abstract][Full Text] [Related]
18. Negative interpretation of ambiguous bodily symptoms among illness-anxious individuals: Exploring the role of developmental and maintenance constructs.
Elhamiasl M; Dehghani M; Heidari M; Vancleef LMG; Khatibi A
Front Psychiatry; 2022; 13():985125. PubMed ID: 36699482
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
20. Quality of life assessment in migraine and relapsing remitting multiple sclerosis: self-perceived health is similar.
Glavor KD; Titlić M; Vuletić G; Mrđen A; Šimunić MM
Neurol Sci; 2019 Dec; 40(12):2549-2554. PubMed ID: 31317351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
